Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer

被引:12
|
作者
Gogineni, Emile [1 ]
Rana, Zaker [1 ]
Soberman, Danielle [1 ]
Sidiqi, Baho [1 ]
D'Andrea, Vincent [1 ]
Lee, Lucille [1 ]
Potters, Louis [1 ]
Parashar, Bhupesh [1 ]
机构
[1] Donald & Barbara Zucker Sch Med Hofstra Northwell, Acad Dept Radiat Med, Hempstead, NY 11549 USA
关键词
EXTERNAL-BEAM RADIOTHERAPY; TRIAL; MONOTHERAPY; SPACER;
D O I
10.1016/j.ijrobp.2020.11.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Low-dose-rate (LDR) brachytherapy and stereotactic body radiation therapy (SBRT) have both shown acceptable outcomes in the treatment of low- and intermediate-risk prostate cancer. Minimal data have been published directly comparing rates of biochemical control and toxicity with these 2 modalities. We hypothesize that LDR and SBRT will provide similar rates of biochemical control. Methods and Materials: All low- and intermediate-risk patients with prostate cancer treated definitively with SBRT or LDR between 2010 and 2018 were captured. Phoenix definition was used for biochemical failure. Independent t tests were used to compare baseline characteristics, and repeated measure analysis of variance test was used to compare American Urologic Association (AUA) and the Expanded Prostate Cancer Index Composite (EPIC) scores between treatment arms over time. Biochemical control was estimated using the Kaplan-Meier method. Differences in acute and late toxicity were assessed via Pearson chi(2). Results: In the study, 219 and 118 patients were treated with LDR and SBRT. Median follow-up was 4.3 years (interquartile range, 3.1-6.1). All patients treated with LDR received 125.0 Gy in a single fraction. SBRT consisted of 42.5 Gy in 5 fractions. Five-year biochemical control for LDR versus SBRT was 91.6% versus 97.6% (P =.108). LDR patients had a larger increase in mean AUA scores at 1 month (17.2 vs 10.3, P <.001) and 3 months posttreatment (14.0 vs 9.7, P <.001), and in mean EPIC scores at 1 month (15.7 vs 13.8, P <.001). There was no significant difference between LDR and SBRT in late grade 3 genitourinary toxicity (0.9% vs 2.5%, P =.238); however, LDR had lower rates of late grade 3 gastrointestinal toxicity (0.0% vs 2.5%, P =.018). Conclusions: Our data show similar biochemical control and genitourinary toxicity rates at 5 years for both SBRT and LDR, with slightly higher gastrointestinal toxicity with SBRT and higher AUA and EPIC scores with LDR. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:1232 / 1242
页数:11
相关论文
共 50 条
  • [41] Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?
    Tabata, Ryuji
    Kimura, Takahiro
    Kuruma, Hidetoshi
    Sasaki, Hiroshi
    Kido, Masahito
    Miki, Kenta
    Takahashi, Hiroyuki
    Aoki, Manabu
    Egawa, Shin
    [J]. CANCER MEDICINE, 2016, 5 (09): : 2314 - 2322
  • [42] Quality of Life Outcomes for Low- and Intermediate-Risk Prostate Cancer Patients Treated With 5-Fraction Stereotactic Body Radiation Therapy
    Kaplan, I. D.
    Meier, R.
    Beckman, A. C.
    Henning, G.
    Woodhouse, S. A.
    Williamson, S. K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E249 - E249
  • [43] Comparison of Active Surveillance, Low-Dose-Rate Brachytherapy, Stereotactic Ablative Body Radiation Therapy, and Standard External Beam in Low-Risk Prostate Cancer
    Musunuru, H. B.
    Sethukavalan, P.
    Cheung, P.
    Morton, G.
    D'Alimonte, L.
    Deabreu, A.
    Mamedov, A.
    Zhang, L.
    Chung, H.
    Loblaw, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S447 - S447
  • [44] Comparison of the Biochemical Recurrence Risk between Radical Prostatectomy and Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer
    Martinez, Pablo F.
    Belisle, Diego F.
    Cristallo, Christian
    Tobia, Ignacio
    Damia, Oscar
    Villamil, Wenceslao
    Giudice, Carlos R.
    [J]. ARCHIVOS ESPANOLES DE UROLOGIA, 2015, 68 (08): : 655 - 660
  • [45] Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer
    Morris, W. James
    Keyes, Mira
    Spadinger, Ingrid
    Kwan, Winkle
    Liu, Mitchell
    McKenzie, Michael
    Pai, Howard
    Pickles, Tom
    Tyldesley, Scott
    [J]. CANCER, 2013, 119 (08) : 1537 - 1546
  • [46] The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer
    Tanaka, Nobumichi
    [J]. PROSTATE INTERNATIONAL, 2023, 11 (03) : 127 - 133
  • [47] Biochemical Control and Toxicity Outcomes of SBRT vs LDR Brachytherapy in the Treatment of Low and Intermediate Risk Prostate Cancer
    Gogineni, E.
    Rana, Z. H.
    Cai, H.
    Soberman, D.
    D'Andrea, V.
    Lee, L.
    Potters, L.
    Parashar, B.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E862 - E862
  • [48] Decreased PSA Nadir as a Result of Dose-Escalated Stereotactic Body Radiation for Patients With Low- and Intermediate-Risk Prostate Cancer
    Rana, Zaker
    Potters, Louis
    Lee, Lucille
    Cox, Brett
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E28 - E29
  • [49] Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
    Kim, Hun Jung
    Phak, Jeong Hoon
    Kim, Woo Chul
    [J]. RADIATION ONCOLOGY JOURNAL, 2016, 34 (04): : 260 - 264
  • [50] Patterns of Recurrence After Low-Dose-Rate Prostate Brachytherapy: A Population-Based Study of 2223 Consecutive Low- and Intermediate-Risk Patients
    Lo, Andrea C.
    Morris, W. James
    Pickles, Tom
    Keyes, Mira
    McKenzie, Michael
    Tyldesley, Scott
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (04): : 745 - 751